Mitsubishi Chemical Medience Markets POCT Device To The U.S. And Canada
This article was originally published in PharmAsia News
Tokyo-based medical device maker Mitsubishi Chemical Medience began marketing compact automated immunoassay analyzer Pathfast to the U.S. and Canada. FDA approved the device along with N-Terminal proBNP (brain natriuretic peptide) testing as a marker of congestive heart failure. A point-of-care testing device, PATHFAST is used for night and emergency care testing and has been marketed in Europe and Korea. The company has signed distribution agreements with North American distributors and hopes to get six more test reagents approved by the FDA by this December. Mitsubishi Chemical estimates within three years that Pathfast will reach 10 percent of the BNP testing market with ¥4 billion in sales. (Click here for more - Japanese language
You may also be interested in...
Infographic timeline looks at key moments in the history of vaccine development, from the first vaccine against smallpox to the polio field trial involving 1.8 million children to the flurry of vaccines created by ‘the scientist who saved more lives than all other scientists combined.’
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.